Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am Psychiatric Assoc. 2010;167(7):748–51.

Article  Google Scholar 

Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203.

Article  PubMed  PubMed Central  Google Scholar 

Shetty S, Bose A. Schizophrenia and periodontal disease: An oro-neural connection? A cross-sectional epidemiological study. J Indian Soc Periodontol. 2014;18(1):69.

Article  PubMed  PubMed Central  Google Scholar 

Lam RW. Psychopharmacology for the clinician. J Psychiatry Neurosci. 2013;38(2):E5.

Article  PubMed  PubMed Central  Google Scholar 

Simon G. Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA. 2001;286(23):3003–4.

Article  CAS  PubMed  Google Scholar 

Nurnberg HG, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999;60(9):921.

Article  Google Scholar 

Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. Aust Prescr. 2019;42(5):152.

Article  PubMed  PubMed Central  Google Scholar 

Weiden PJ. Switching antipsychotic medications: not enough, too often, or just right? Am Psychiatric Assoc. 2011;168:882–4.

Article  Google Scholar 

Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. Does switching to a new antipsychotic improve outcomes?: Data from the CATIE trial. Schizophr Res. 2009;107(1):22–9.

Article  PubMed  Google Scholar 

Bobo WV. Switching antipsychotics: Why, When, and How? Psychiatr Times. 2013;30(3):26.

Google Scholar 

Bernardo M, Vieta E, Ruiz JS, Rico-Villademoros F, Álamo C, Bobes J, et al. Recommendations for switching antipsychotics A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment. 2011;4(3):150–68.

Article  PubMed  Google Scholar 

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon B. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9(1):1–9.

Article  Google Scholar 

Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17–29.

Article  PubMed  Google Scholar 

Kumar M, Chavan B, Sidana A, Das SJ. Efficacy and tolerability of clozapine versus quetiapine in treatment-resistant schizophrenia. Indian J Psychol Med. 2017;39(6):770–6.

Article  PubMed  PubMed Central  Google Scholar 

Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res. 2008;99(1–3):13–22.

Article  PubMed  Google Scholar 

Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Res. 2008;99(13):13–22.

Article  Google Scholar 

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010;10(1):1–11.

Article  Google Scholar 

Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder. Clin Drug Investig. 2004;24(5):275–86.

Article  CAS  PubMed  Google Scholar 

Organization WH. Mental health systems in selected low-and middle-income countries a WHO-AIMS cross-national analysis. Geneva: World Health Organization; 2009.

Google Scholar 

Ibrahim AW, Yahya S, Pindar SK, Wakil MA, Garkuwa A, Sale S. Prevalence and predictors of sub-optimal medication adherence among patients with severe mental illnesses in a tertiary psychiatric facility in Maiduguri, North-eastern Nigeria. Pan Afr Med J. 2015;21(1):39.

PubMed  PubMed Central  Google Scholar 

Asfaw G. Antipsychotic Medications Switch and Contributing Factors among Ambulatory Patients with Schizophrenia at Amanuel Specialized Mental Hospital, Addis Ababa, Ethiopia 2017.

Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–51.

Article  PubMed  Google Scholar 

AlHewiti A. Adherence to long-term therapies and beliefs about medications. Int J Family Med. 2014;2014: 479596.

Article  PubMed  PubMed Central  Google Scholar 

Alene M, Wiese MD, Angamo MT, Bajorek BV, Yesuf EA, Wabe NT. Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population. BMC Clin Pharmacol. 2012;12(1):1–9.

Article  Google Scholar 

World Health Organization. International Classification of Functioning, Disability, and Health: Children & Youth Version: ICF-CY. Geneva: World Health Organization; 2007.

Google Scholar 

DIN PCB. International classification of functioning, disability and health. 2001.

Moges S, Belete T, Mekonen T, Menberu M. Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study. J Mental Health Syst. 2021;15(1):1–12.

Google Scholar 

Hugenholtz GW, Heerdink ER, Nolen WA, Egberts AC. Less medication switching after initial start with atypical antipsychotics. Eur Neuropsychopharmacol. 2004;14(1):1–5.

Article  CAS  PubMed  Google Scholar 

Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, et al. Antipsychotic medication utilization trends among Texas veterans: 1997–2002. Ann Pharmacother. 2008;42(9):1229–38.

Article  PubMed  Google Scholar 

Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry. 2002;159(9):1534–40.

Article  PubMed  Google Scholar 

Schneider AL. Switching antipsychotics in the treatment of schizophrenia: a two-year comp arison study of patient characteristics and psychiatric service use. Montreal: McGill University; 2006.

Google Scholar 

Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, et al. The evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective. Schizophr Res. 2011;130(1–3):40–6.

Article  PubMed  Google Scholar 

Eloff I, Esterhuysen W, Odayar K. Antipsychotic use in a resource-limited setting: Findings in an Eastern Cape psychiatric hospital. South African J Psychiatry. 2017;23:1093.

Article  Google Scholar 

Ayano G. Journal of Neuropsychopharmacology & Mental Health. 2016.

Assefa N, Sié A, Wang D, Korte ML, Hemler EC, Abdullahi YY, et al. Reported barriers to healthcare access and service disruptions caused by COVID-19 in Burkina Faso Ethiopia, and Nigeria: a telephone survey. Am J Trop Med Hygiene. 2021;105(2):323.

Article  CAS  Google Scholar 

Guerin PJ, Singh-Phulgenda S, Strub-Wourgaft N. The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world? F1000Research. 2020;9:255.

Article  Google Scholar 

Bačar Bole C, Pišlar M, Šen M, Tavčar R, Mrhar A. Switching antipsychotics: results from 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders. Acta Pharm. 2017;67(1):99–112.

Article  Google Scholar 

Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry. 1997;58(10):63–72.

PubMed  Google Scholar 

Eloff I, Esterhuysen W, Odayar K. Antipsychotic use in a resource-limited setting: findings in an eastern cape psychiatric hospital. S Afr J Psychiatry. 2017;23:1093.

Google Scholar 

Roussidis A, Kalkavoura C, Dimelis D, Theodorou A, Ioannidou I, Mellos E, et al. Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study. Ann Gen Psychiatry. 2013;12(1):1–7.

Article  Google Scholar 

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.

Article  PubMed  Google Scholar 

De Nayer A, Windhager E, Irmansyah L, Larmo I, Lindenbauer B, Rittmannsberger H, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract. 2003;7(1):59–66.

Article  PubMed  Google Scholar 

Burns T, Chabannes J, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18(4):201–8.

Article  CAS  PubMed  Google Scholar 

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):1163–71.

Article  PubMed  Google Scholar 

Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum HJ. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol. 2006;26(6):666–7.

Article  PubMed  Google Scholar 

Angermeyer MC, Kühn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull. 1990;16(2):293–307.

Article  CAS